Autem Therapeutics Email Format

Biotechnology ResearchNew Hampshire, United States11-50 Employees

Autem Therapeutics is a privately held biotechnology company focused on oncology therapeutics and bioelectric medical technology, headquartered in Hanover, New Hampshire. It is pursuing a non-invasive, non-toxic treatment platform intended for multiple cancers, including hepatocellular carcinoma and glioblastoma, as well as other solid tumors. Central to its approach is a device named AutEMsys that administers customized electromagnetic frequencies; early feasibility data suggest possible tumor shrinkage and improvements in patient quality of life and survival. The therapy has FDA Breakthrough Device designation for the treatment of advanced hepatocellular carcinoma. Autem Therapeutics expects to pursue FDA Investigational Device Exemptions to begin clinical trials in HCC and GBM in the second half of 2025. As a relatively small biotechnology company, it operates in the biotechnology research sector with a pan-cancer approach that relies on non-invasive cancer therapies.

Sign up for free to view info

Company overview Employee directory